High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy
about
HDL particle number and size as predictors of cardiovascular diseaseAdvances in the Study of the Antiatherogenic Function and Novel Therapies for HDLThe role of advanced lipid testing in the prediction of cardiovascular diseaseNiacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease.Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.Serum lipid profile and its association with hypertension in Bangladesh.Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study.Impact of estimated HDL particle size via the ratio of HDL-C and apoprotein A-I on short-term prognosis of diabetic patients with stable coronary artery disease.The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspectiveEffects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.Quantification of HDL particle concentration by calibrated ion mobility analysis.Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men.Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study.Do all components of the metabolic syndrome cluster together in U.S. Hispanics/Latinos? Results from the Hispanic Community Health study/Study of Latinos.Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- MiceLipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.Complementary Cholesterol-Lowering Response of a Phytosterol/α-Lipoic Acid Combination in Obese Zucker Rats.Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study).Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating RosImpact of Obesity and Metabolic Syndrome on Immunity.Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.Superiority of lipoprotein particle number to detect associations with arterial thickness and stiffness in obese youth with and without prediabetes.Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.Polyphenol rich olive oils improve lipoprotein particle atherogenic ratios and subclasses profile: A randomized, crossover, controlled trialEthnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizesCirculating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish populationRole of HDL in those with diabetes.Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy.Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).High-density lipoprotein-based drug discovery for treatment of atherosclerosis.Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number: The Multi-Ethnic Study of Atherosclerosis.The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.
P2860
Q26779287-93675673-D669-4884-8470-E7EDCCCA489BQ26801507-DC5CAE3D-8D18-43C2-BE4D-D5F46DDF7F78Q26859507-4209CA63-B929-4926-B472-27882274C01BQ28086787-6FE3B7FC-CCE8-47A3-B6F3-DCCF2E7F49CCQ30364133-CBEF545D-BA8D-4BA1-BD6E-2E2F5D42731FQ33737098-22531032-B3E1-4241-8A14-C4FB78EC48D6Q33818877-F9BB3155-DFAD-4A82-80BE-9DA1D72933E6Q33863779-FB753414-7037-49DE-8ACB-B64EFE30BED0Q34090408-668D5033-1417-461D-A682-58822F4FB016Q34260460-9034C8D0-0284-4AB6-8650-F6BB1BB284ABQ34513438-ECF7A4FC-F0D5-4B34-A268-C64BBCB9138CQ34644974-1B95F82E-0EAB-4E2B-887E-F2B1E9E55E50Q35051225-C3BF9E4D-55A1-477C-9D3D-C335B4C62F4DQ35073968-ADBA4931-7878-4ACE-80C1-3C56E9356DECQ35129072-87C0AC5A-1179-4055-ACFA-082F63B72BA3Q35181281-C934E61D-EC42-456D-809A-7F044CB867AAQ35221749-3676B6E6-1BD6-4C7D-9AD0-0A2A11CEE9A8Q35688647-D86A556A-1082-4E2C-A47F-2617DE478245Q35705485-2E9066F2-6DDB-494B-A312-B393CF95F775Q35847854-6D6C6C6C-39C5-42BC-A0B9-38FBD0F6834BQ35903590-ED1B60EC-1DAB-4232-8AE2-C43E6604C253Q35931637-AD071AAB-6028-4A5A-A590-8703EE285D71Q36345240-AEEE9E4D-663F-4BCB-9EAB-D16B406FFFE9Q36359891-9CE9FD70-F2C0-489A-9654-01D37AD10A22Q36476998-411DD481-C073-41F4-A9DF-E8CDBEA0A0AAQ36560360-74A1A4E8-6402-41FD-B0C7-1130DE5839EAQ36609592-B3908F39-2B61-4730-89EA-E248C89A3AB3Q36775168-FC9A3E73-C9DF-4E57-98D2-0897147BF61BQ36926879-528AF8B4-B2ED-4CEC-B960-E9635F22C8F8Q37031309-ABB29D47-32C5-4A95-968B-DEA9CA9220C0Q37104660-749555B2-8E37-4939-B856-D6A734590D01Q37133870-393D6BE5-4FFB-47B3-AC85-178C1D4F359AQ37240800-B59ACCA8-EF92-471D-AFBC-7A2DAECD7C6BQ37412661-261CEEEE-87A9-45E9-85AB-FBBAEC576B86Q38221965-F5841B52-ED24-4DAA-8F7D-4916C9C74DF2Q38363617-3081539C-8740-4FE5-8547-11FE3642DE09Q38377434-2826CFA1-EF71-4D00-955E-34BB792C29E0Q38506490-B4DFA4F0-8D06-4DCB-B375-C34EB09E6444Q38837647-FD9B6E01-7325-4579-B22B-3FB99FCA8558Q38896299-FA80E0F5-A6C3-4B09-854F-7079D3A72404
P2860
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-density lipoprotein chole ...... sk after potent statin therapy
@en
High-density lipoprotein chole ...... k after potent statin therapy.
@nl
type
label
High-density lipoprotein chole ...... sk after potent statin therapy
@en
High-density lipoprotein chole ...... k after potent statin therapy.
@nl
prefLabel
High-density lipoprotein chole ...... sk after potent statin therapy
@en
High-density lipoprotein chole ...... k after potent statin therapy.
@nl
P2093
P2860
P921
P1433
P1476
High-density lipoprotein chole ...... sk after potent statin therapy
@en
P2093
Paul M Ridker
Robert J Glynn
Samia Mora
P2860
P304
P356
10.1161/CIRCULATIONAHA.113.002671
P407
P577
2013-09-03T00:00:00Z